Key Metrics<\/h2>\n
“},{“component”:”hc_space”,”id”:”Snp7Z”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””}]},{“component”:”hc_column”,”id”:”ErUW9″,”column_width”:”col-md-12″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_column”,”id”:”kWJom”,”column_width”:”col-md-6″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_counter”,”id”:”NCNZY”,”css_classes”:”col-center “,”custom_css_classes”:””,”custom_css_styles”:””,”title”:”biosimilars approved “,”count_to”:”600″,”icon”:”im-dna-2″,”icon_style”:””,”icon_image”:””,”style”:”icon-horizontal”,”from”:””,”speed”:””,”interval”:””,”before_text”:””,”separator”:””,”text_size”:”text-xl”,”text_size_2″:”text-m”,”icon_size”:”text-xxl”}]},{“component”:”hc_column”,”id”:”8fdim”,”column_width”:”col-md-6″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_counter”,”id”:”rLeey”,”css_classes”:”col-center “,”custom_css_classes”:””,”custom_css_styles”:””,”title”:”therapeutic areas”,”count_to”:”10″,”icon”:”im-target”,”icon_style”:””,”icon_image”:””,”style”:”icon-horizontal”,”from”:””,”speed”:””,”interval”:””,”before_text”:” Covering over”,”separator”:””,”text_size”:”text-xl”,”text_size_2″:”text-m”,”icon_size”:”text-xxl”}]},{“component”:”hc_space”,”id”:”OgZMm”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”s”,”height”:””},{“component”:”hc_button”,”id”:”v2pZW”,”css_classes”:”col-center “,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:”square-border”,”size”:”btn-lg”,”position”:”left”,”animation”:false,”text”:”Biosimilar Medicines Approvals Map”,”link_type”:”lightbox”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:false,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/biosimilar-medicines-approvals\/”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}]}],”section_settings”:””},”section_eKAz2″:{“component”:”hc_section”,”id”:”section_eKAz2″,”section_width”:””,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”vertical_row”:””,”box_middle”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”section_content”:[{“component”:”hc_column”,”id”:”column_moizk”,”column_width”:”col-md-6″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:”boxed bg-cover “,”custom_css_classes”:””,”custom_css_styles”:” background-color: rgba(0, 0, 0, 0.6)!important;”,”main_content”:[{“component”:”hc_space”,”id”:”c9Cx5″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”s”,”height”:””},{“component”:”hc_title_tag”,”id”:”aXdLz”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”text”:”Welcome!”,”tag”:”h2″},{“component”:”hc_text_block”,”id”:”nVxnG”,”css_classes”:”white “,”custom_css_classes”:””,”custom_css_styles”:”margin-top: 14px;”,”content”:”IGBA is hosting its third annual Global Biosimilars Week on November 14-18. The goal of this social media campaign is to raise awareness of the powerful impact of biosimilar medicines and provide key resources for advocates and interested parties. “},{“component”:”hc_space”,”id”:”Itm6E”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”s”,”height”:””},{“component”:”hc_title_tag”,”id”:”mcXOV”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”color:white !important”,”text”:”Support the Social Media Campaign”,”tag”:”h4″},{“component”:”hc_text_block”,”id”:”2kUDT”,”css_classes”:”white “,”custom_css_classes”:””,”custom_css_styles”:”margin-top: 14px;”,”content”:”All week, we invite stakeholders, patients, health care professionals and their organizations around the world to share their resources and information about biosimilar medicines in social media with the hashtag #GlobalBiosimilarsWeek. Together we can create a movement to advance access of biosimilar medicines to patients around the world.”},{“component”:”hc_button”,”id”:”puiuA”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:”square”,”size”:”btn-lg”,”position”:”left”,”animation”:false,”text”:”Download & Share Flyer”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/flyer.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false},{“component”:”hc_button”,”id”:”17CbE”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-top:20px;”,”icon”:””,”style”:”square”,”size”:”btn-lg”,”position”:”left”,”animation”:false,”text”:”Download Social Toolkit”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/toolkit.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false},{“component”:”hc_text_block”,”id”:”QriK9″,”css_classes”:”white “,”custom_css_classes”:””,”custom_css_styles”:”margin-top: 14px;”,”content”:”Don’t miss out and subscribe <\/a>to hear the latest news on this campaign.<\/b>“}]}],”section_settings”:{“component”:”hc_section_image”,”id”:”section-image”,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/05\/Global-biosimilar-week-2022-background-3-1024×576.jpg|1080|1920|633″,”full_screen”:false,”full_screen_height”:””,”parallax”:true,”bleed”:””,”ken_burn”:””,”bg_pos”:””,”overlay”:””}},”section_34T6B”:{“component”:”hc_section”,”id”:”section_34T6B”,”section_width”:””,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”vertical_row”:””,”box_middle”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”background-color:white;”,”section_content”:[{“component”:”hc_column”,”id”:”AHk5o”,”column_width”:”col-md-12″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”padding: 51px 80px 32px 80px; text-align: center;”,”main_content”:[{“component”:”hc_video”,”id”:”xFKpz”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”link”:”https:\/\/www.youtube.com\/watch?v=ITO49g5BO9A”,”width”:”500″,”height”:”350″,”autoplay”:false,”loop”:false,”controls”:true,”muted”:false},{“component”:”hc_space”,”id”:”eFFWV”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_wp_editor”,”id”:”SCsr2″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n<\/p>\n The campaign theme this year is the Value of Biosimilar medicines. Each day of the week we encourage supporters to share different aspects of biosimilar\u2019s value in social media. Click the arrows below for more details and see sample messages in the social toolkit<\/a><\/strong>.<\/p>\n “},{“component”:”hc_space”,”id”:”dQfUA”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”s”,”height”:””},{“component”:”hc_grid_table”,”id”:”IbjOy”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”font-weight: bold;”,”content”:[{“component”:”hc_text_block”,”id”:”VAfaR”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”<\/i> Day 1 (Nov 14) <\/a>“},{“component”:”hc_accordion”,”id”:”MbOu6″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”name_1″:”Biosimilars: Value for patients”,”icon_1″:””,”icon_style_1″:””,”icon_image_1″:””,”content_1″:[{“component”:”hc_wp_editor”,”id”:”2cNG5″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n<\/ul>\n “}],”name_2″:””,”icon_2″:””,”icon_style_2″:””,”icon_image_2″:””,”content_2″:[],”name_3″:””,”icon_3″:””,”icon_style_3″:””,”icon_image_3″:””,”content_3″:[],”name_4″:””,”icon_4″:””,”icon_style_4″:””,”icon_image_4″:””,”content_4″:[],”name_5″:””,”icon_5″:””,”icon_style_5″:””,”icon_image_5″:””,”content_5″:[],”name_6″:””,”icon_6″:””,”icon_style_6″:””,”icon_image_6″:””,”content_6″:[],”name_7″:””,”icon_7″:””,”icon_style_7″:””,”icon_image_7″:””,”content_7″:[],”name_8″:””,”icon_8″:””,”icon_style_8″:””,”icon_image_8″:””,”content_8″:[],”name_9″:””,”icon_9″:””,”icon_style_9″:””,”icon_image_9″:””,”content_9″:[],”name_10″:””,”icon_10″:””,”icon_style_10″:””,”icon_image_10″:””,”content_10″:[],”open_type”:”visible”,”time”:”1″,”open”:”1″},{“component”:”hc_text_block”,”id”:”dCjKF”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”<\/i> Day 2 (Nov 15) <\/a>“},{“component”:”hc_accordion”,”id”:”lvMnR”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”name_1″:”Biosimilars: Value for healthcare professionals, providers and clinical practice”,”icon_1″:””,”icon_style_1″:””,”icon_image_1″:””,”content_1″:[{“component”:”hc_wp_editor”,”id”:”ivyzu”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n<\/ul>\n “}],”name_2″:””,”icon_2″:””,”icon_style_2″:””,”icon_image_2″:””,”content_2″:[],”name_3″:””,”icon_3″:””,”icon_style_3″:””,”icon_image_3″:””,”content_3″:[],”name_4″:””,”icon_4″:””,”icon_style_4″:””,”icon_image_4″:””,”content_4″:[],”name_5″:””,”icon_5″:””,”icon_style_5″:””,”icon_image_5″:””,”content_5″:[],”name_6″:””,”icon_6″:””,”icon_style_6″:””,”icon_image_6″:””,”content_6″:[],”name_7″:””,”icon_7″:””,”icon_style_7″:””,”icon_image_7″:””,”content_7″:[],”name_8″:””,”icon_8″:””,”icon_style_8″:””,”icon_image_8″:””,”content_8″:[],”name_9″:””,”icon_9″:””,”icon_style_9″:””,”icon_image_9″:””,”content_9″:[],”name_10″:””,”icon_10″:””,”icon_style_10″:””,”icon_image_10″:””,”content_10″:[],”open_type”:””,”time”:””,”open”:””},{“component”:”hc_text_block”,”id”:”sfGtD”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”<\/i> Day 3 (Nov 16) <\/a>“},{“component”:”hc_accordion”,”id”:”5tzLW”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”name_1″:”Biosimilars: Value for governments and healthcare systems”,”icon_1″:””,”icon_style_1″:””,”icon_image_1″:””,”content_1″:[{“component”:”hc_wp_editor”,”id”:”NtD8B”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n<\/ul>\n \\n<\/li>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n<\/ul>\n “}],”name_2″:””,”icon_2″:””,”icon_style_2″:””,”icon_image_2″:””,”content_2″:[],”name_3″:””,”icon_3″:””,”icon_style_3″:””,”icon_image_3″:””,”content_3″:[],”name_4″:””,”icon_4″:””,”icon_style_4″:””,”icon_image_4″:””,”content_4″:[],”name_5″:””,”icon_5″:””,”icon_style_5″:””,”icon_image_5″:””,”content_5″:[],”name_6″:””,”icon_6″:””,”icon_style_6″:””,”icon_image_6″:””,”content_6″:[],”name_7″:””,”icon_7″:””,”icon_style_7″:””,”icon_image_7″:””,”content_7″:[],”name_8″:””,”icon_8″:””,”icon_style_8″:””,”icon_image_8″:””,”content_8″:[],”name_9″:””,”icon_9″:””,”icon_style_9″:””,”icon_image_9″:””,”content_9″:[],”name_10″:””,”icon_10″:””,”icon_style_10″:””,”icon_image_10″:””,”content_10″:[],”open_type”:””,”time”:””,”open”:””},{“component”:”hc_text_block”,”id”:”FsBhL”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”<\/i> Day 4 (Nov 17)<\/a>“},{“component”:”hc_accordion”,”id”:”4y9Nj”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”name_1″:”Biosimilars: Value for regulators “,”icon_1″:””,”icon_style_1″:””,”icon_image_1″:””,”content_1″:[{“component”:”hc_wp_editor”,”id”:”yDxW1″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n \\t<\/p>\n \\n \\t<\/p>\n \\n<\/ul>\n “}],”name_2″:””,”icon_2″:””,”icon_style_2″:””,”icon_image_2″:””,”content_2″:[],”name_3″:””,”icon_3″:””,”icon_style_3″:””,”icon_image_3″:””,”content_3″:[],”name_4″:””,”icon_4″:””,”icon_style_4″:””,”icon_image_4″:””,”content_4″:[],”name_5″:””,”icon_5″:””,”icon_style_5″:””,”icon_image_5″:””,”content_5″:[],”name_6″:””,”icon_6″:””,”icon_style_6″:””,”icon_image_6″:””,”content_6″:[],”name_7″:””,”icon_7″:””,”icon_style_7″:””,”icon_image_7″:””,”content_7″:[],”name_8″:””,”icon_8″:””,”icon_style_8″:””,”icon_image_8″:””,”content_8″:[],”name_9″:””,”icon_9″:””,”icon_style_9″:””,”icon_image_9″:””,”content_9″:[],”name_10″:””,”icon_10″:””,”icon_style_10″:””,”icon_image_10″:””,”content_10″:[],”open_type”:””,”time”:””,”open”:””},{“component”:”hc_text_block”,”id”:”ok8Mj”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”<\/i> Day 5 (Nov 18) <\/a>“},{“component”:”hc_text_block”,”id”:”tUdYI”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”text-align:left;”,”content”:”Join the Biosimilars Movement!”}],”rows”:”5″,”cols”:”2″,”full-border”:false,”no-borders”:false,”full-mobile”:false}]},{“component”:”hc_column”,”id”:”YMvFl”,”column_width”:”col-md-12″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_adv_slider”,”id”:”3RhEm”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content_1″:[{“component”:”hc_quote”,”id”:”UF9Rp”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”text”:”When competition kicks in, we need policies in place supporting the reinvestment of the savings in more patients having access. \\nOur last interview during our third Global Biosimilars Week features Dr Cary Adams<\/a>, CEO of the Union for International Cancer Control (UICC) and Suzette Kox<\/a>, IGBA Secretary General. It covers the relatively new UICC initiative, namely a different approach to access by the Access to Oncology Medicines (ATOM) Coalition and how biosimilar medicines companies can play a role in the Coalition\u2019s ambition of improving access to essential cancer medicines.\\n\\n “},{“component”:”hc_space”,”id”:”0V7RR”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-bottom: 0!important;”,”size”:”xs”,”height”:”0″},{“component”:”hc_video”,”id”:”Y7CqO”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”link”:”https:\/\/www.youtube.com\/watch?v=tppWOr-es4Y”,”width”:””,”height”:”350″,”autoplay”:false,”loop”:false,”controls”:true,”muted”:false},{“component”:”hc_space”,”id”:”OakdO”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_button”,”id”:”vXKll”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:”circle”,”size”:””,”position”:”center”,”animation”:false,”text”:”watch past interviews”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:false,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/interviews\/”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}]}],”section_settings”:””},”section_87LXy”:{“component”:”hc_section”,”id”:”section_87LXy”,”section_width”:””,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”vertical_row”:””,”box_middle”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”background-color:white;”,”section_content”:[{“component”:”hc_column”,”id”:”column_OQ69B”,”column_width”:”col-md-5″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_space”,”id”:”XUqik”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_image”,”id”:”sH0j1″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/11\/Embracing-Science-with-Confidence.jpg|834|588|1116″,”alt”:””,”thumb_size”:”large”}]},{“component”:”hc_column”,”id”:”column_03bit”,”column_width”:”col-md-7″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_space”,”id”:”kufGw”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_wp_editor”,”id”:”ttFRn”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n\\n<\/p>\n \\n\\n<\/p>\n \\n\\n<\/p>\n \\n\\nBiosimilar medicines hold the potential to enable equitable access to biologic therapies for patients around the world. The IGBA\u2019s 2021 Biosimilar medicines Access Policy Blueprint identified four key areas where global collaborative action can help achieve the potential for biosimilar medicines.\\n\\nThis paper further elaborates on one of the key areas: Enhancing Regulatory Efficiency for Greater Access.\\n\\nIt discusses how the revised 2022 WHO Biosimilars Guideline (the Guideline) provides a timely opportunity to collectively re-evaluate the way in which regulatory requirements can better advance biosimilar access. The Guideline defines globally acceptable principles for licensing biological products that can be used to harmonize biosimilar medicines regulations around the world. If cohesively adopted by national regulatory authorities, the Guideline can promote more efficient regulatory systems to provide patients with earlier access to safe, effective, high-quality, and lowercost biosimilar medicines.”},{“component”:”hc_space”,”id”:”NcoIw”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_button”,”id”:”k5bRi”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:”square”,”size”:”btn-lg”,”position”:”left”,”animation”:false,”text”:”Download IGBA White Paper “,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.igbamedicines.org\/doc\/Embracing-Science-with-Confidence-9-11-2022.pdf”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false},{“component”:”hc_space”,”id”:”w50I9″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””}]}],”section_settings”:””},”section_zPzkK”:{“component”:”hc_section”,”id”:”section_zPzkK”,”section_width”:””,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”vertical_row”:””,”box_middle”:””,”css_classes”:”white “,”custom_css_classes”:””,”custom_css_styles”:”background-color:#5b3a8c; padding:31px 24px 23px 20px”,”section_content”:[{“component”:”hc_column”,”id”:”cPfKi”,”column_width”:”col-md-12″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_wp_editor”,”id”:”uXXMS”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n<\/p>\n View these educational modules to learn how the biosimilar landscape began and how patients and health care systems benefit from biosimilar medicines around the globe.<\/p>\n “},{“component”:”hc_space”,”id”:”daW3y”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-bottom: 0!important;”,”size”:”xs”,”height”:”0″},{“component”:”hc_tab”,”id”:”uQC8H”,”css_classes”:”col-center “,”custom_css_classes”:””,”custom_css_styles”:””,”name_1″:”Chapter 1: \\nSince 1980, biological medicines, which are highly complex treatments made by or derived from a biological source, have grown to become an indispensable tool in modern medicine. These safe and effective medicines are targeted to treat many rare and serious diseases and millions of patients have already benefited from these treatments.”},{“component”:”hc_space”,”id”:”lOmpI”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-bottom: 0!important;”,”size”:”xs”,”height”:”0″},{“component”:”hc_button”,”id”:”U5zeS”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:”square”,”size”:””,”position”:”center”,”animation”:false,”text”:”OPEN”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/module1.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}],”name_2″:”Chapter 2: \\nHealth care systems around the globe are under financial stress due to the pandemic, an aging population and rising prevalence of chronic conditions, with pharmaceutical spending expected to reach $1.6 trillion USD globally in the coming years. Biological medicines, while an important tool in treating certain conditions, come at a very high cost and hence are inaccessible for many patients.”},{“component”:”hc_space”,”id”:”d6aef”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-bottom: 0!important;”,”size”:”xs”,”height”:”0″},{“component”:”hc_button”,”id”:”OprSC”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:null,”size”:”btn-xs”,”position”:”center”,”animation”:false,”text”:”OPEN”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/module2.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}],”name_3″:”Chapter 3: \\nBiosimilar medicines are biological medicines that are developed to be highly similar to an existing biological medicine, but are more cost-effective. Today, hundreds of biosimilar medicines have been approved around the globe, which brought competition to the marketplace after patent expiry of the original biological. This has produced huge savings and eased financial stress on health care systems and substantially increased patients access to biological treatments.”},{“component”:”hc_space”,”id”:”s85AW”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-bottom: 0!important;”,”size”:”xs”,”height”:”0″},{“component”:”hc_button”,”id”:”8XIUw”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:null,”size”:”btn-xs”,”position”:”center”,”animation”:false,”text”:”OPEN”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/module3.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}],”name_4″:”Chapter 4: \\nWith biosimilar medicines, patients and healthcare providers benefit from quality-assured and efficacious therapeutic alternatives. Biosimilar medicine development is target-oriented and comparative, requiring significant investment and state-of-the-art technologies. Extensive evidence is required to demonstrate that a biosimilar medicine is as safe and effective as its reference biologic. Additionally, the same high regulatory standards apply as for any other medicine.”},{“component”:”hc_space”,”id”:”AFmzl”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”margin-bottom: 0!important;”,”size”:”xs”,”height”:”0″},{“component”:”hc_button”,”id”:”HDsBM”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:null,”size”:”btn-xs”,”position”:”center”,”animation”:false,”text”:”OPEN”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/module4.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}],”name_5″:”Chapter 5: \\nGreater competition introduced by biosimilar medicines has many benefits for patients, providers, and health care systems around the world. Biosimilar medicines give providers a broader range of treatment options for their patients and give more patients access to biological treatments. Additionally, by representing cost-effective alternatives to reference biologicals, biosimilar medicines offer health care systems huge savings for the same clinical outcome.”},{“component”:”hc_space”,”id”:”4dvjB”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_button”,”id”:”TDdH5″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:null,”size”:”btn-xs”,”position”:”center”,”animation”:false,”text”:”OPEN”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/module5.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}],”name_6″:”Chapter 6: \\nBiosimilar medicines have become an integral part of our health care systems. Today, they are internationally recognized for expanding access to life-saving treatments. Building on the experience and the success of biosimilar medicines supports their increased uptake and safeguards the medical supply chain.”},{“component”:”hc_space”,”id”:”l09bJ”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_button”,”id”:”ZUmex”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”icon”:””,”style”:null,”size”:”btn-xs”,”position”:”center”,”animation”:false,”text”:”OPEN”,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/module6.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false}],”name_7″:””,”icon_7″:””,”icon_style_7″:””,”icon_image_7″:””,”content_7″:[],”name_8″:””,”icon_8″:””,”icon_style_8″:””,”icon_image_8″:””,”content_8″:[],”style”:”justified”,”pills”:true,”animation”:””,”animation_icon”:””,”layout”:””},{“component”:”hc_space”,”id”:”512Ug”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””}]},{“component”:”hc_column”,”id”:”aklFj”,”column_width”:”col-md-4″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”text-align: center;”,”main_content”:[{“component”:”hc_image_box”,”id”:”TBnRL”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/09\/SUCESS-STORY.png|169|300|1036″,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/Biosimilars-a-science-success-story.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false,”icon”:””,”style”:””,”icon_position”:””,”image_animation”:””,”icon_animation”:””,”thumb_size”:”large”,”icon_hidden”:true,”img_box_inner_caption”:true,”caption_img_box”:””,”alt”:””},{“component”:”hc_text_block”,”id”:”Ckzey”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”Biosimilars: a science success story”},{“component”:”hc_space”,”id”:”DWDms”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_image_box”,”id”:”1JIOn”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/09\/GREG.png|169|300|1039″,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/Greg-Story.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false,”icon”:””,”style”:””,”icon_position”:””,”image_animation”:””,”icon_animation”:””,”thumb_size”:”large”,”icon_hidden”:true,”img_box_inner_caption”:true,”caption_img_box”:””,”alt”:””},{“component”:”hc_text_block”,”id”:”faiRR”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”Greg\u2019s Story: 37, Los Angeles, CA, Ulcerative Colitis “}]},{“component”:”hc_column”,”id”:”OyUHC”,”column_width”:”col-md-4″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”text-align: center;”,”main_content”:[{“component”:”hc_image_box”,”id”:”2lbOs”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/09\/in-essence-the-same.png|169|300|1037″,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/Biosimilar-in-essence-the-same.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false,”icon”:””,”style”:””,”icon_position”:””,”image_animation”:””,”icon_animation”:””,”thumb_size”:”large”,”icon_hidden”:true,”img_box_inner_caption”:true,”caption_img_box”:””,”alt”:””},{“component”:”hc_text_block”,”id”:”h5hDE”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”Biosimilar: in essence the same”},{“component”:”hc_space”,”id”:”4gzBJ”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”size”:”xs”,”height”:””},{“component”:”hc_image_box”,”id”:”wMXZE”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/09\/Akaimi.png|169|300|1040″,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/Akaimi-Story.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false,”icon”:””,”style”:””,”icon_position”:””,”image_animation”:””,”icon_animation”:””,”thumb_size”:”large”,”icon_hidden”:true,”img_box_inner_caption”:true,”caption_img_box”:””,”alt”:””},{“component”:”hc_text_block”,”id”:”7LVTB”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”Akaimi\u2019s Story: 44 , San Antonio, TX, Leukemia”}]},{“component”:”hc_column”,”id”:”Pswxg”,”column_width”:”col-md-4″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”text-align: center;”,”main_content”:[{“component”:”hc_image_box”,”id”:”oUzAS”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”image”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/wp-content\/uploads\/2022\/09\/Eileen.png|169|300|1038″,”link_type”:”classic”,”lightbox_animation”:””,”caption”:””,”inner_caption”:false,”new_window”:true,”link”:”https:\/\/www.globalbiosimilarsweek.org\/2024\/redirections\/Eileen-Story.html”,”link_content”:[],”lightbox_size”:””,”scrollbox”:false,”icon”:””,”style”:””,”icon_position”:””,”image_animation”:””,”icon_animation”:””,”thumb_size”:”large”,”icon_hidden”:true,”img_box_inner_caption”:true,”caption_img_box”:””,”alt”:””},{“component”:”hc_text_block”,”id”:”2mXg1″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”content”:”Eileen\u2019s Story: 28, New York, NY Crohn\u2019s Disease”}]}],”section_settings”:””},”section_oSfda”:{“component”:”hc_section”,”id”:”section_oSfda”,”section_width”:””,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”vertical_row”:””,”box_middle”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:”background-color:#white; padding:31px 24px 23px 20px”,”section_content”:[{“component”:”hc_column”,”id”:”PWf0V”,”column_width”:”col-md-12″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_wp_editor”,”id”:”aVjAp”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\n \\n<\/p>\n View organizations or activities helping to build a better future with biosimilar medicines.<\/p>\n \\n<\/p>\n \\n<\/p>\n Open List of Participating Organizations<\/a><\/u><\/p>\n \\n<\/p>\nStrengthening Healthcare\\nThe Value of Biosimilar Medicines<\/h2>\n
\\n \\t<\/p>\n
\\n \\t<\/p>\n
\\n \\t<\/p>\n
\\n \\t<\/p>\n
\\n \\t<\/p>\n
Suzette Kox, IGBA Secretary General<\/b>“,”style”:”double_quote”,”author”:””}],”image_1″:””,”content_2″:[{“component”:”hc_quote”,”id”:”eG3OH”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”text”:”With 15 years of positive biosimilar medicines contribution to patient health and healthcare system sustainability, the challenges and remedies to efficient use of biosimilar medicines are well known.
Julie Mar\u00e9chal-Jamil, Co-Chair, IGBA Biosimilars Committee<\/b>“,”style”:”double_quote”,”author”:””}],”image_2″:””,”content_3″:[{“component”:”hc_quote”,”id”:”EfDT2″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”text”:”The COVID-19 global health crisis has led governments and the entire healthcare community to rethink and rebuild healthcare systems; this includes focusing on their ability to efficiently deliver access to biologic therapies and to effectively address non-communicable diseases.
Sudarshan Jain, IGBA Past Chair<\/b>“,”style”:”double_quote”,”author”:””}],”image_3″:””,”content_4″:[],”image_4″:””,”content_5″:[],”image_5″:””,”content_6″:[],”image_6″:””,”outer_arrows”:false,”vertical_middle_arrows”:false,”visible_arrows”:false,”nav_inner”:false,”trigger”:””,”animation”:””,”data_options”:””}]}],”section_settings”:””},”section_qFJ8F”:{“component”:”hc_section”,”id”:”section_qFJ8F”,”section_width”:””,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”vertical_row”:””,”box_middle”:””,”css_classes”:”white “,”custom_css_classes”:””,”custom_css_styles”:”background-color:#5b3a8c; padding:31px 24px 23px 20px”,”section_content”:[{“component”:”hc_column”,”id”:”column_XpMuh”,”column_width”:”col-md-12″,”animation”:””,”animation_time”:””,”timeline_animation”:””,”timeline_delay”:””,”timeline_order”:””,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”main_content”:[{“component”:”hc_wp_editor”,”id”:”aupND”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”<\/p>\nInterviews<\/h2>\n
An IGBA Biosimilars Committee White Paper<\/b><\/h3>\n
\nEmbracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline<\/b><\/h2>\n
\nBiosimilar Resources<\/h2>\n
THE ERA OF BIOLOGICAL MEDICINES<\/b>“,”icon_1″:””,”icon_style_1″:””,”icon_image_1″:””,”content_1″:[{“component”:”hc_wp_editor”,”id”:”hqVoG”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”
<\/a>\\n<\/p>\n\\nThe era of biological medicines<\/strong><\/h4>\n
BIOLOGICAL MEDICINES \u2013 THE MAJOR SOCIAL AND ECONOMIC CHALLENGES<\/b>“,”icon_2″:””,”icon_style_2″:””,”icon_image_2″:””,”content_2″:[{“component”:”hc_wp_editor”,”id”:”gVdoK”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”
<\/a>\\n<\/p>\n\\nBiological medicines \u2013 the major social and economic challenges<\/strong><\/h4>\n
BIOSIMILAR MEDICINES \u2013 RISING TO THE COST CHALLENGE<\/b>“,”icon_3″:””,”icon_style_3″:””,”icon_image_3″:””,”content_3″:[{“component”:”hc_wp_editor”,”id”:”PJDJj”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”
<\/a>\\n<\/p>\n\\nBiosimilar medicines \u2013 rising to the cost challenge<\/strong><\/h4>\n
BIOSIMILAR MEDICINES \u2013 A COMMITMENT TO SCIENTIFIC EXCELLENCE <\/b>“,”icon_4″:””,”icon_style_4″:””,”icon_image_4″:””,”content_4″:[{“component”:”hc_wp_editor”,”id”:”XrK72″,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”
<\/a>\\n<\/p>\n\\nBiosimilar medicines \u2013 a commitment to scientific excellence <\/strong><\/h4>\n
THE BENEFITS OF BIOSIMILAR MEDICINES<\/b>“,”icon_5″:””,”icon_style_5″:””,”icon_image_5″:””,”content_5″:[{“component”:”hc_wp_editor”,”id”:”HIxvS”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”
<\/a>\\n<\/p>\n\\nThe benefits of biosimilar medicines<\/strong><\/h4>\n
BUILDING ON THE EXPERIENCE AND SUCCESS OF BIOSIMILAR MEDICINES <\/b>“,”icon_6″:””,”icon_style_6″:””,”icon_image_6″:””,”content_6″:[{“component”:”hc_wp_editor”,”id”:”SwpoQ”,”css_classes”:””,”custom_css_classes”:””,”custom_css_styles”:””,”editor_content”:”
<\/a>\\n<\/p>\n\\nBuilding on the experience and success of biosimilar medicines <\/strong><\/h4>\n
#GlobalBiosimilarsWeek Around the Globe<\/h2>\n
PARTICIPATING IN GBW 
IGBA MEMBER 
GBW MEDIA PARTNER<\/p>\n